company background image

Cryosite ASX:CTE Stock Report

Last Price


Market Cap







27 Sep, 2022


Company Financials
CTE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance6/6
Financial Health5/6

CTE Stock Overview

Cryosite Limited offers outsourced clinical trials logistic services in Australia.

Cryosite Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cryosite
Historical stock prices
Current Share PriceAU$0.71
52 Week HighAU$0.87
52 Week LowAU$0.33
1 Month Change-2.05%
3 Month Change13.49%
1 Year Change88.16%
3 Year Change1,525.00%
5 Year Change361.29%
Change since IPO62.50%

Recent News & Updates

Aug 19
Should You Be Adding Cryosite (ASX:CTE) To Your Watchlist Today?

Should You Be Adding Cryosite (ASX:CTE) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

May 02
Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?

Do Cryosite's (ASX:CTE) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

CTEAU Life SciencesAU Market

Return vs Industry: CTE exceeded the Australian Life Sciences industry which returned -51.1% over the past year.

Return vs Market: CTE exceeded the Australian Market which returned -11.9% over the past year.

Price Volatility

Is CTE's price volatile compared to industry and market?
CTE volatility
CTE Average Weekly Movement8.1%
Life Sciences Industry Average Movement9.4%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.3%

Stable Share Price: CTE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CTE's weekly volatility (8%) has been stable over the past year.

About the Company

199922John Hogg

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry.

Cryosite Fundamentals Summary

How do Cryosite's earnings and revenue compare to its market cap?
CTE fundamental statistics
Market CapAU$34.90m
Earnings (TTM)AU$1.36m
Revenue (TTM)AU$11.76m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTE income statement (TTM)
Cost of RevenueAU$4.92m
Gross ProfitAU$6.84m
Other ExpensesAU$5.47m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)0.028
Gross Margin58.16%
Net Profit Margin11.60%
Debt/Equity Ratio0%

How did CTE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is CTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTE?

Other financial metrics that can be useful for relative valuation.

CTE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA13.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does CTE's PE Ratio compare to its peers?

CTE PE Ratio vs Peers
The above table shows the PE ratio for CTE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average58.3x
EZZ EZZ Life Science Holdings
GSS Genetic Signatures
TRJ Trajan Group Holdings
LGP Little Green Pharma
CTE Cryosite

Price-To-Earnings vs Peers: CTE is good value based on its Price-To-Earnings Ratio (25.6x) compared to the peer average (58.3x).

Price to Earnings Ratio vs Industry

How does CTE's PE Ratio compare vs other companies in the Global Life Sciences Industry?

Price-To-Earnings vs Industry: CTE is good value based on its Price-To-Earnings Ratio (25.6x) compared to the Global Life Sciences industry average (29.8x)

Price to Earnings Ratio vs Fair Ratio

What is CTE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CTE's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTE (A$0.72) is trading below our estimate of fair value (A$2.7)

Significantly Below Fair Value: CTE is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Cryosite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cryosite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether Cryosite is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Cryosite competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Cryosite performed over the past 5 years?

Past Performance Score


Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CTE has high quality earnings.

Growing Profit Margin: CTE's current net profit margins (11.6%) are higher than last year (6.5%).

Past Earnings Growth Analysis

Earnings Trend: CTE has become profitable over the past 5 years, growing earnings by 43.1% per year.

Accelerating Growth: CTE's earnings growth over the past year (109%) exceeds its 5-year average (43.1% per year).

Earnings vs Industry: CTE earnings growth over the past year (109%) exceeded the Life Sciences industry 15.3%.

Return on Equity

High ROE: CTE's Return on Equity (73.3%) is considered outstanding.

Discover strong past performing companies

Financial Health

How is Cryosite's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CTE's short term assets (A$8.3M) exceed its short term liabilities (A$3.7M).

Long Term Liabilities: CTE's short term assets (A$8.3M) do not cover its long term liabilities (A$15.9M).

Debt to Equity History and Analysis

Debt Level: CTE is debt free.

Reducing Debt: CTE has not had any debt for past 5 years.

Debt Coverage: CTE has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CTE has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Cryosite current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Cryosite Dividend Yield vs Market
How does Cryosite dividend yield compare to the market?
SegmentDividend Yield
Company (Cryosite)1.4%
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Life Sciences)0.4%
Analyst forecast in 3 Years (Cryosite)n/a

Notable Dividend: CTE's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.78%).

High Dividend: CTE's dividend (1.4%) is low compared to the top 25% of dividend payers in the Australian market (7.13%).

Stability and Growth of Payments

Stable Dividend: CTE is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CTE is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: CTE is not paying a notable dividend for the Australian market.

Cash Payout to Shareholders

Cash Flow Coverage: CTE is not paying a notable dividend for the Australian market.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


John Hogg





Mr. John Hogg has been Chief Executive Officer at Cryosite Limited since October 15, 2020. Mr. Hogg joined Cryosite in July 2018 and was promoted to General Manager of Operations on the 1st December 2019....

CEO Compensation Analysis

John Hogg's Compensation vs Cryosite Earnings
How has John Hogg's remuneration changed compared to Cryosite's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022AU$251kAU$227k


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021AU$337kAU$220k


Compensation vs Market: John's total compensation ($USD162.74K) is below average for companies of similar size in the Australian market ($USD278.67K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CTE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: CTE's board of directors are considered experienced (5.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

ASX:CTE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 May 22BuyAU$128,358Mark KerrIndividual195,000AU$0.70
03 Mar 22BuyAU$671,014Andrew KrogerIndividual1,560,499AU$0.43
28 Feb 22BuyAU$321,205Andrew KrogerIndividual716,239AU$0.45

Ownership Breakdown

What is the ownership structure of CTE?
Owner TypeNumber of SharesOwnership Percentage
Private Companies8,948,43918.3%
General Public10,373,73621.3%
Individual Insiders26,398,31554.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 20 shareholders own 78.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Andrew Kroger
15,223,777A$10.9m0%no data
Shr Pty. Ltd.
4,487,258A$3.2m0%no data
Process Wastewater Technologies Pty Limited
2,832,667A$2.0m0%no data
DMX Asset Management Limited
Alistair Strong
2,025,000A$1.4m1.25%no data
Allan Robins
1,880,750A$1.3m34.34%no data
Gary Robins
1,880,750A$1.3m23.94%no data
Bryan Dulhunty
1,330,000A$951.0k0%no data
Mark Kerr
1,259,707A$900.7k194.67%no data
Linda Kerr
1,259,707A$900.7k194.67%no data
John Hogg
650,000A$464.8k0%no data
Sunnyit Pty Ltd
559,518A$400.1k0%no data
HFA Administration Pty Ltd
480,000A$343.2k0%no data
Jane Milliken
350,917A$250.9k0%no data
Stephen Roberts
337,707A$241.5k-6.89%no data
Ginga Pty Ltd, Asset Management Arm
Castlereagh Equity Pty Ltd
300,000A$214.5k0%no data
M N J Holdings Pty Ltd
214,931A$153.7k0%no data
Michele Robins
200,000A$143.0k0%no data
Cell Care Australia Pty Limited
74,065A$53.0k0%no data

Company Information

Cryosite Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Cryosite Limited
  • Ticker: CTE
  • Exchange: ASX
  • Founded: 1999
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$34.899m
  • Shares outstanding: 48.81m
  • Website:

Number of Employees


  • Cryosite Limited
  • 13a Ferndell Street
  • South Granville
  • New South Wales
  • 2142
  • Australia


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTEASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2002
CTECHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2002

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Annual Earnings2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.